NASDAQ:LGND Ligand Pharmaceuticals (LGND) Stock Forecast, Price & News $58.75 -0.42 (-0.71%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$58.21▼$59.4050-Day Range$58.75▼$70.7252-Week Range$57.77▼$97.65Volume96,433 shsAverage Volume116,675 shsMarket Capitalization$1.02 billionP/E Ratio40.80Dividend YieldN/APrice Target$109.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ligand Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.8% Upside$109.75 Price TargetShort InterestHealthy5.05% of Float Sold ShortDividend StrengthN/ASustainability-1.57Upright™ Environmental ScoreNews Sentiment0.79Based on 18 Articles This WeekInsider TradingAcquiring Shares$237,520 Bought Last QuarterProj. Earnings Growth-19.69%From $3.81 to $3.06 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.3.03 out of 5 starsMedical Sector39th out of 966 stocksPharmaceutical Preparations Industry9th out of 445 stocks 3.5 Analyst's Opinion Consensus RatingLigand Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $109.75, Ligand Pharmaceuticals has a forecasted upside of 86.8% from its current price of $58.75.Amount of Analyst CoverageLigand Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.05% of the float of Ligand Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverLigand Pharmaceuticals has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Ligand Pharmaceuticals has recently decreased by 6.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLigand Pharmaceuticals does not currently pay a dividend.Dividend GrowthLigand Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreLigand Pharmaceuticals has received a 67.85% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antihypertensives (C02)", "Pneumococcal vaccines", "Quinolones", "Fosphenytoin", "Antifungal medication (D01) ", and "Bevacizumab" products. See details.Environmental SustainabilityThe Environmental Impact score for Ligand Pharmaceuticals is -1.57. Previous Next 3.2 News and Social Media Coverage News SentimentLigand Pharmaceuticals has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Ligand Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest6 people have searched for LGND on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ligand Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ligand Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $237,520.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.40% of the stock of Ligand Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.19% of the stock of Ligand Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Ligand Pharmaceuticals are expected to decrease by -19.69% in the coming year, from $3.81 to $3.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ligand Pharmaceuticals is 40.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.19.Price to Earnings Ratio vs. SectorThe P/E ratio of Ligand Pharmaceuticals is 40.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 136.56.Price to Earnings Growth RatioLigand Pharmaceuticals has a PEG Ratio of 0.78. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioLigand Pharmaceuticals has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ligand Pharmaceuticals (NASDAQ:LGND) StockLigand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.Read More LGND Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGND Stock News HeadlinesOctober 4, 2023 | finance.yahoo.comLigand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should KnowOctober 3, 2023 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Short Interest UpdateOctober 4, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. October 2, 2023 | americanbankingnews.comZacks Research Weighs in on Ligand Pharmaceuticals Incorporated's Q1 2024 Earnings (NASDAQ:LGND)September 29, 2023 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Rating of "Buy" by AnalystsSeptember 28, 2023 | finance.yahoo.comLigand Pharmaceuticals (LGND) Gains But Lags Market: What You Should KnowSeptember 28, 2023 | finance.yahoo.comLigand (LGND) Acquires Certain Assets of Novan for $12.2MSeptember 28, 2023 | markets.businessinsider.comBuy Rating for Ligand: Strategic Acquisition and Promising Clinical Data Drive Positive ForecastOctober 4, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. September 27, 2023 | marketwatch.comLigand Pharmaceuticals Buys Novan Assets for $12.2 MillionSeptember 27, 2023 | finance.yahoo.comLigand Acquires Assets of Novan, Inc. for $12.2 MillionSeptember 27, 2023 | americanbankingnews.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Gap Up After Insider Buying ActivitySeptember 26, 2023 | finance.yahoo.comLigand Appoints Martine Zimmermann to its Board of DirectorsSeptember 26, 2023 | benzinga.comLigand Pharmaceuticals Chief Executive Officer Trades $237K In Company StockSeptember 26, 2023 | americanbankingnews.comTodd C. Davis Acquires 4,000 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) StockSeptember 26, 2023 | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) CEO Todd C. Davis Purchases 4,000 SharesSeptember 26, 2023 | finance.yahoo.comInsider Buying: CEO Todd Davis Acquires 4,000 Shares of Ligand Pharmaceuticals IncSeptember 22, 2023 | finance.yahoo.comLigand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaSeptember 21, 2023 | finance.yahoo.comLigand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active ControlSeptember 19, 2023 | markets.businessinsider.comLigand Pharma Updates Annual Guidance As It Spins Out Pelican SubsidiarySeptember 19, 2023 | markets.businessinsider.comWhere Ligand Pharmaceuticals Stands With AnalystsSeptember 19, 2023 | finance.yahoo.comLigand (LGND) to Spin Out Pelican Subsidiary, Updates '23 ViewSeptember 19, 2023 | markets.businessinsider.comCraig-Hallum Reaffirms Their Buy Rating on Ligand Pharma (LGND)September 19, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Virpax Pharmaceuticals (VRPX)September 18, 2023 | msn.comLigand spins out Pelican unit as separate company, updates guidanceSeptember 12, 2023 | finance.yahoo.comLigand Pharmaceuticals (LGND) Dips More Than Broader Markets: What You Should KnowSeptember 1, 2023 | seekingalpha.comLigand: Nothing Exciting Stands OutSee More Headlines Receive LGND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address LGND Company Calendar Last Earnings8/08/2023Today10/04/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:LGND CUSIP53220K50 CIK886163 Webwww.ligand.com Phone(858) 550-7500Fax858-550-1826Employees76Year FoundedN/APrice Target and Rating Average Stock Price Forecast$109.75 High Stock Price Forecast$144.00 Low Stock Price Forecast$90.00 Forecasted Upside/Downside+86.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$1.44 Trailing P/E Ratio40.80 Forward P/E Ratio15.96 P/E Growth0.81Net Income$-33,360,000.00 Net Margins14.54% Pretax Margin50.96% Return on Equity6.82% Return on Assets5.49% Debt Debt-to-Equity RatioN/A Current Ratio9.42 Quick Ratio8.50 Sales & Book Value Annual Sales$196.24 million Price / Sales5.19 Cash Flow$4.99 per share Price / Cash Flow11.78 Book Value$35.37 per share Price / Book1.66Miscellaneous Outstanding Shares17,350,000Free Float15,550,000Market Cap$1.02 billion OptionableOptionable Beta1.03 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Todd C. Davis Ph.D. (Age 62)CEO & Director Comp: $743.49kMr. Matthew E. Korenberg (Age 48)Pres & COO Comp: $760.99kMr. Octavio Espinoza (Age 52)Chief Financial Officer Comp: $457.19kMr. Andrew T. Reardon J.D. (Age 48)Chief Legal Officer & Sec. Comp: $480.16kSimon LatimerHead of Investor RelationsMr. Todd PettingillDirector of Corp. Devel.Ms. Audrey Warfield-GrahamChief People OfficerDr. Keith MarschkeSr. VP of Biology & Scientific AffairsDr. Vincent D. Antle (Age 54)Sr. VP of Technical Operations & QA - Capitsol Mr. Patrick LucySr. VP & CBO Protein Expression Bus.More ExecutivesKey CompetitorsMannKindNASDAQ:MNKDGeronNASDAQ:GERNOPKO HealthNASDAQ:OPKInnovivaNASDAQ:INVAIntercept PharmaceuticalsNASDAQ:ICPTView All CompetitorsInsiders & InstitutionsTodd C DavisBought 4,000 shares on 9/22/2023Total: $237,520.00 ($59.38/share)Barclays PLCSold 365 shares on 9/21/2023Ownership: 0.083%California State Teachers Retirement SystemSold 642 shares on 8/21/2023Ownership: 0.114%Cornerstone Capital Inc.Sold 2,489 shares on 8/21/2023Ownership: 0.064%Teachers Retirement System of The State of KentuckyBought 281 shares on 8/21/2023Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions LGND Stock - Frequently Asked Questions Should I buy or sell Ligand Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LGND shares. View LGND analyst ratings or view top-rated stocks. What is Ligand Pharmaceuticals' stock price forecast for 2023? 4 analysts have issued 12-month price targets for Ligand Pharmaceuticals' shares. Their LGND share price forecasts range from $90.00 to $144.00. On average, they predict the company's share price to reach $109.75 in the next twelve months. This suggests a possible upside of 86.8% from the stock's current price. View analysts price targets for LGND or view top-rated stocks among Wall Street analysts. How have LGND shares performed in 2023? Ligand Pharmaceuticals' stock was trading at $66.80 at the beginning of the year. Since then, LGND stock has decreased by 12.1% and is now trading at $58.75. View the best growth stocks for 2023 here. Are investors shorting Ligand Pharmaceuticals? Ligand Pharmaceuticals saw a decline in short interest during the month of September. As of September 15th, there was short interest totaling 825,000 shares, a decline of 6.2% from the August 31st total of 879,200 shares. Based on an average trading volume of 94,200 shares, the short-interest ratio is currently 8.8 days. Approximately 5.1% of the shares of the company are sold short. View Ligand Pharmaceuticals' Short Interest. When is Ligand Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our LGND earnings forecast. How were Ligand Pharmaceuticals' earnings last quarter? Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) posted its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported $1.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.76 by $0.66. The biotechnology company earned $26.37 million during the quarter, compared to analyst estimates of $24.74 million. Ligand Pharmaceuticals had a trailing twelve-month return on equity of 6.82% and a net margin of 14.54%. The company's revenue was down 47.4% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.14) earnings per share. What ETFs hold Ligand Pharmaceuticals' stock? ETFs with the largest weight of Ligand Pharmaceuticals (NASDAQ:LGND) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Franklin Genomic Advancements ETF (HELX), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What guidance has Ligand Pharmaceuticals issued on next quarter's earnings? Ligand Pharmaceuticals updated its FY 2023 earnings guidance on Wednesday, September, 27th. The company provided earnings per share (EPS) guidance of $5.10-$5.25 for the period, compared to the consensus EPS estimate of $4.98. The company issued revenue guidance of $124.00 million-$126.00 million, compared to the consensus revenue estimate of $127.05 million. What is John L. Higgins' approval rating as Ligand Pharmaceuticals' CEO? 1 employees have rated Ligand Pharmaceuticals Chief Executive Officer John L. Higgins on Glassdoor.com. John L. Higgins has an approval rating of 100% among the company's employees. This puts John L. Higgins in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Ligand Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Cisco Systems (CSCO), Illumina (ILMN) and Gilead Sciences (GILD). What is Ligand Pharmaceuticals' stock symbol? Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND." How do I buy shares of Ligand Pharmaceuticals? Shares of LGND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ligand Pharmaceuticals' stock price today? One share of LGND stock can currently be purchased for approximately $58.75. How much money does Ligand Pharmaceuticals make? Ligand Pharmaceuticals (NASDAQ:LGND) has a market capitalization of $1.02 billion and generates $196.24 million in revenue each year. The biotechnology company earns $-33,360,000.00 in net income (profit) each year or $1.44 on an earnings per share basis. How can I contact Ligand Pharmaceuticals? Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The official website for the company is www.ligand.com. The biotechnology company can be reached via phone at (858) 550-7500, via email at investors@ligand.com, or via fax at 858-550-1826. This page (NASDAQ:LGND) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ligand Pharmaceuticals Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.